Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy
The injection of botulinum neurotoxin A into the prostate represents an alternative, minimal
 invasive treatment in patient with lower urinary tract symptoms (LUTS) associated to benign
 prostatic hyperplasia (BPH).

 Objective: To evaluate the effectiveness of BTA in treating patients with symptomatic BPH and
 unsatisfactory response to combined medical therapy.
Inclusion Criteria:

 -  Moderate-to-severe LUTS as determined by the International Prostate Symptom Score

 -  Mean peak urinary flow rate of no more than 15 mL/s with a voided volume of at least
 150 mL, or postvoid residual urine volume (PVR) of more than 100 ml and urodynamic
 parameters indicative of bladder outlet obstruction (BOO) according to International
 Continence Society

 Exclusion Criteria:

 -  Patients with neurogenic voiding disorders, prostate or bladder cancer, bladder
 stones, urethral stricture, chronic bladder catheterization were excluded from the
 study.